At therapeutic decision points, highly annotated, prospective tumor and blood samples are collected

• Enrolled subjects are followed throughout their lifetime or for as long as they decide to participate in the study

• A Biorepository of DNA, RNA and proteins will be linked with patient outcomes data via web-based tools

CASTLE provides a broad-based, clinically validated panel of biomarkers and partnerships with diagnostic laboratories

• A dynamic biomarker panel is evolving

• Tissue collections will enable reanalysis as new molecular markers and mutations are discovered

CASTLE bridges the gap

• CASTLE provides immediate access to technologies, information and data to treating physicians and community health providers leading to better outcomes for patients via customized treatment – consequently treat the whole person rather than just the disease

• CASTLE will have a registry of tissue like no other in the world, available no only to investigator in the United States, but worldwide.